Anti-GD2 mAb therapy is well-tolerated in patients with high-risk neuroblastoma, and a Phase III clinical trial found that the addition of anti-GD2 mAb, interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF) to retinoic acid therapy significantly improved event-free survival (EFS) and OS in high-risk neuroblastoma (18–20). The gene discussed is CSF2; the disease is neuroblastoma.